Literature DB >> 2664195

Investigational drugs for treatment use: an avenue of hope for minority populations.

R V Veiga, C A Reid.   

Abstract

The Food and Drug Administration in its efforts to facilitate the drug approval process so that promising treatments may be offered to seriously ill or dying patients has established an innovative regulation, commonly known as the Treatment Investigational New Drugs (TIND). The benefits of this new policy should prove to be particularly appealing to black Americans. Traditionally blacks, due to numerous social, political, economic, and cultural factors, have had the poorest health status of any other population in the United States. The implementation of strategies to eradicate such factors will ultimately provide considerable improvement of the health status of blacks. Until then, the utilization of the TIND may prove to be one of the most significant influences in the advancement of our health care. Barriers to the use of the TIND regulation in the black community must be addressed as well.

Entities:  

Mesh:

Year:  1989        PMID: 2664195      PMCID: PMC2626001     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  3 in total

1.  Barriers to medical care among adult blacks: what happens to the uninsured?

Authors:  H W Neighbors; J S Jackson
Journal:  J Natl Med Assoc       Date:  1987-05       Impact factor: 1.798

2.  FDA's newly designated treatment INDs.

Authors:  F E Young; S L Nightingale
Journal:  JAMA       Date:  1988-07-08       Impact factor: 56.272

3.  The FDA's new procedures for the use of investigational drugs in treatment.

Authors:  F E Young; J A Norris; J A Levitt; S L Nightingale
Journal:  JAMA       Date:  1988-04-15       Impact factor: 56.272

  3 in total
  1 in total

1.  Medicaid policies for HIV-related prescription drugs.

Authors:  R J Buchanan; S R Smith
Journal:  Health Care Financ Rev       Date:  1994
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.